An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors

Genetic and Phenotypic Diversity in Breast Tumor Metastases

(2014) V. Almendro et al.   CANCER RESEARCH

Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

(2014) J. J. Tao et al.   Science Signaling

Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression

(2014) Evgeny V. Denisov et al.   Scientific Reports

Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity

(2014) Vanessa Almendro et al.   Cell Reports

Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy

(2013) D. Habermehl et al.   JOURNAL OF RADIATION RESEARCH

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

(2013) Jeffrey S Ross et al.   MODERN PATHOLOGY

Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments

(2013) Felicitas Merz et al.   NEURO-ONCOLOGY

High-Throughput Methods for Combinatorial Drug Discovery

(2013) X. Sun et al.   Science Translational Medicine

Novel Phenotypic Fluorescent Three-Dimensional Platforms for High-throughput Drug Screening and Personalized Chemotherapy

(2013) Changge Fang et al.   Journal of Cancer

Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance

(2012) Elizabeth S. Nakasone et al.   CANCER CELL

Redefining Clinical Trials: The Age of Personalized Medicine

(2012) Gayathri Vaidyanathan   CELL

Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks

(2012) Michael J. Lee et al.   CELL

Impact of Genomics on Personalized Cancer Medicine

(2012) C. L. Arteaga et al.   CLINICAL CANCER RESEARCH

Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?

(2012) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of small molecule cancer drugs: Successes, challenges and opportunities

(2012) Swen Hoelder et al.   Molecular Oncology

Sequence analysis of mutations and translocations across breast cancer subtypes

(2012) Shantanu Banerji et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Combinatorial drug therapy for cancer in the post-genomic era

(2012) Bissan Al-Lazikani et al.   NATURE BIOTECHNOLOGY

Overcoming implementation challenges of personalized cancer therapy

(2012) Funda Meric-Bernstam et al.   Nature Reviews Clinical Oncology

Drug development and clinical trials—the path to an approved cancer drug

(2012) Eric H. Rubin et al.   Nature Reviews Clinical Oncology

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip

(2012) R. Farra et al.   Science Translational Medicine

Multi-Reservoir Bioadhesive Microdevices for Independent Rate-Controlled Delivery of Multiple Drugs

(2012) Hariharasudhan D. Chirra et al.   Small

Adaptive clinical trials in oncology

(2011) Donald A. Berry   Nature Reviews Clinical Oncology

The productivity crisis in pharmaceutical R&D

(2011) Fabio Pammolli et al.   NATURE REVIEWS DRUG DISCOVERY

Triple-Negative Breast Cancer: An Unmet Medical Need

(2011) C. A. Hudis et al.   ONCOLOGIST

Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study

(2011) S. Roychowdhury et al.   Science Translational Medicine

Analysis of Food and Drug Administration-Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines

(2010) S. L. Holbeck et al.   MOLECULAR CANCER THERAPEUTICS

Management of breast cancer with targeted agents: importance of heterogenicity

(2010) Serena Di Cosimo et al.   Nature Reviews Clinical Oncology

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

Personalized medicine in oncology: the future is now

(2010) Richard L. Schilsky   NATURE REVIEWS DRUG DISCOVERY

Spending on new drug development

(2009) Christopher Paul Adams et al.   HEALTH ECONOMICS

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

(2008) C.-l. Dai et al.   CANCER RESEARCH

Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts

(2008) J. H.E. Baker et al.   CLINICAL CANCER RESEARCH